Pifithrin-α (PFTα)
(Synonyms: 2-(2-亚氨基-4,5,6,7-四氢苯并噻唑-3-基)-1-P-甲苯基乙酮氢溴酸盐,Pifithrin hydrobromide; PFTα hydrobromide) 目录号 : GC10538
Pifithrin-α是一种p53抑制剂。
Cas No.:63208-82-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pifithrin-α(PFT-α) is a p53 inhibitor[1]. Pifithrin-α widely used in neuroscience to block neuronal apoptotic cell death[2]. Pifithrin-α is also a potent stimulant of aryl hydrocarbon receptor (AhR) [3].
Pifithrin-α (10 µM;48h) reduces meth-induced degeneration of dopaminergic neurons[4]. Treatment with Pifithrin-α(1 µM; 12-24 h) prevents ROS formation in hMp84-overexpressing A375 cells[5]. The IC50 of TPT for HepG2 cells after 10 µµ PFTα pretreated(1-100 µM; 2 h), was 4.8 to 14.4 folds lower than the effect of TPT alone. PFTα decreases the p-p53 levels and p-p53 activity, not affects p53 expression in p53 positive tumor cells[6].
Pifithrin-α (2 mg/kg; i.v) reduced the number of apoptotic cells in the ischemic brain by inhibiting the binding of p53 to its DNA sites as it reduced the expression of the p53-related gene p21WAF[7].Delayed Pifithrin-α (0.4µg/µl; 20µl; i.c.v + 0.2mg/100gm, i.p; twice a day for three days) treatment improved locomotor behavior in stroke rats[8]. Pifithrin-α reduced dopaminergic neurodegeneration in animal models of Parkinson s disease(10 µg)[9], prevented cell death of dopaminergic transplants in 6-OHDA-lesioned rats(2 mg/kg/day; i.p ; 5 days)[10], improved the survival of neuroprogenitor cells in subventricular zone of stroke rats, and reduced traumatic brain injury[11].
References:
[1]. Komarov PG, Komarova EA, et,al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737
[2]. Zhu X, Yu QS, et,al. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem 45:5090-5097
[3]. Hoagland MS, Hoagland EM, et,al. The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther. 2005 Aug;314(2):603-10. doi: 10.1124/jpet.105.084186. Epub 2005 Apr 20. PMID: 15843497.
[4]. Chen YH, Bae E, et,al. Pifithrin-Alpha Reduces Methamphetamine Neurotoxicity in Cultured Dopaminergic Neurons. Neurotox Res. 2019 Aug;36(2):347-356. doi: 10.1007/s12640-019-00050-w. Epub 2019 May 8. PMID: 31069753.
[5]. Moretti D, Del Bello B, et,al. Calpain-3 impairs cell proliferation and stimulates oxidative stress-mediated cell death in melanoma cells. PLoS One. 2015 Feb 6;10(2):e0117258. doi: 10.1371/journal.pone.0117258. PMID: 25658320; PMCID: PMC4319969.
[6]. Guo J, Tang Q, et,al. Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells. Eur J Pharm Sci. 2019 Feb 1;128:61-72. doi: 10.1016/j.ejps.2018.11.024. Epub 2018 Nov 22. PMID: 30472223.
[7].Leker RR, Aharonowiz M, et,al. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol. 2004 Jun;187(2):478-86. doi: 10.1016/j.expneurol.2004.01.030. PMID: 15144874.
[8]. Luo Y, Kuo CC, et,al. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann Neurol. 2009 May;65(5):520-30. doi: 10.1002/ana.21592. PMID: 19475672; PMCID: PMC2690614.
[9]. Liang ZQ, Li YL, et,al. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res 1145:190-203
[10]. Chou J, Greig NH, et,al. Enhanced survival of dopaminergic neuronal transplants in hemi-Parkinsonian rats by the p53 inactivator PFT-α. Cell Transplant 20:1351-1359
[11]. Huang YN, Yang LY, et,al. Neuroprotective effects of pifithrin-α against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis. Sci Rep. 2018 Feb 5;8(1):2368. doi: 10.1038/s41598-018-19654-x. PMID: 29402897; PMCID: PMC5799311.
Pifithrin-α是一种p53抑制剂[1]。Pifithrin-α在神经科学中广泛用于阻断神经元凋亡细胞死亡[2]。Pifithrin-α也是一种强效的芳烃受体(AhR)刺激物[3]。
Pifithrin-α(10 µM;48h)可减少甲基苯丙胺诱导的多巴胺能神经元变性[4]。Pifithrin-α(1 µM;12-24 h)阻止过表达hMp84的A375细胞中ROS的形成[5]。10次µµ ptf α预处理后(1-100 µM; 2 h),TPT对HepG2细胞的IC50比单独使用TPT的效果低4.8 ~ 14.4倍。在p53阳性肿瘤细胞中,ptf α降低p-p53水平和p-p53活性,不影响p53表达[6]。
Pifithrin-α(2 mg/kg; i.v)通过抑制p53与其DNA位点的结合,降低p53相关基因p21WAF的表达,从而减少缺血脑中凋亡细胞的数量[7]。Delayed Pifithrin-α治疗(0.4µg/µl; 20µl; i.c.v + 0.2mg/100gm, i.p; twice a day for three days)可改善脑卒中大鼠的运动行为[8]。Pifithrin-α可减少帕金森病动物模型多巴胺能神经退行性变(10 µg) [9],防止6-OHDA损伤大鼠多巴胺能移植细胞死亡(2 mg/kg/day; i.p ; 5 days) [10],提高脑卒中大鼠脑室下区神经祖细胞存活率,减轻创伤性脑损伤[11]。
| Cell experiment [1]: | |
|
Cell lines |
HepG2 cells |
|
Preparation Method |
Cells seeded in a 96-well plate at a concentration of 105 cells/ml for 24 h, were treated with various does TPT, PFTα alone or both (for this group, cells were pretreated with PFTα for 2 h prior to TPT treatment). After 48 h incubation, the cells were pretreated with PFTα for 2 h prior to TPT treatment) |
|
Reaction Conditions |
1-100 µM; 2 h |
|
Applications |
The IC50 of TPT for HepG2 cells after 10 µµ PFTα pretreated, was lower than the effect of TPT alone. PFTα decreases the p-p53 levels and p-p53 activity. |
| Animal experiment [2]: | |
|
Animal models |
Adult male Sprague-Dawley rats |
|
Preparation Method |
Transient Focal Ischemia Model |
|
Dosage form |
0.4µg/µl; 20µl; i.c.v + 0.2mg/100gm, i.p; twice a day for three days |
|
Applications |
Delayed Pifithrin-α treatment improved locomotor behavior in stroke rats. |
|
References: [1]. Guo J, Tang Q, et,al. Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells. Eur J Pharm Sci. 2019 Feb 1;128:61-72. doi: 10.1016/j.ejps.2018.11.024. Epub 2018 Nov 22. PMID: 30472223. |
|
| Cas No. | 63208-82-2 | SDF | |
| 别名 | 2-(2-亚氨基-4,5,6,7-四氢苯并噻唑-3-基)-1-P-甲苯基乙酮氢溴酸盐,Pifithrin hydrobromide; PFTα hydrobromide | ||
| 化学名 | 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone;hydrobromide | ||
| Canonical SMILES | CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br | ||
| 分子式 | C16H18N2OS.HBr | 分子量 | 367.3 |
| 溶解度 | ≥ 17.45 mg/mL in DMSO, ≥ 7.12 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7226 mL | 13.6129 mL | 27.2257 mL |
| 5 mM | 0.5445 mL | 2.7226 mL | 5.4451 mL |
| 10 mM | 0.2723 mL | 1.3613 mL | 2.7226 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet